All-encompassing Program Led by Diabetes Specialist Team

NCT ID: NCT03497390

Last Updated: 2022-03-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

207 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-31

Study Completion Date

2017-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Obese type 2 diabetic patients are difficult to treat with many unmet needs requiring complex treatment regimens, intensive counselling and emotional support. Traditional anti-diabetic drugs, such as sulphonylureas and insulin, are known to have side-effects of weight gain and can offset the benefits of glycemic control and increase cardiovascular risks. Aside from these therapeutic challenges, psychological needs of these obese diabetic patients due to anxiety, stigmatization, stress, depression cannot be adequately addressed in a busy clinic setting. Here, the investigators propose to conduct this translational study aiming to compare the effects of a multi-component care program with personalized drug regimen augmented by behavioural therapy with psychological support and peer influence, led by a diabetes specialist team on metabolic control and psychobehavioural parameters in obese type 2 diabetic participants with poor glycemic control (glycated hemoglobin \[HbA1c\]\>8%) versus usual care. The 1-year multi-component program will be followed by a 2-year observational period in the EMERALD group. Outcome measures will be assessed in all participants in the EMERALD and usual care group at 1-year and 3-year. The primary outcome was between-group differences in HbA1c from baseline to year 1 and year 3. The secondary outcomes were the proportion of patients who attained key performance indexes (KPIs; defined by reduction \[Δ\] in HbA1c≥0.5%, ΔSBP≥5 mmHg, ΔLDL-cholesterol≥0.5 mmol/L and Δbody weight≥3%) and BMI\<25 kg/m2. systolic/diastolic BP, lipid levels (total cholesterol, LDL-cholesterol, triglyceride, high-density lipoprotein cholesterol \[HDL-cholesterol\]), obesity indices (body weight, BMI and waist circumference) and patient-reported outcomes. The latter included self-care and treatment adherence (assessed by 16-item Summary for Diabetes Self-Care Activities \[SDSCA-16\]), empowerment (assessed by Chinese Diabetes Empowerment Scale-10 \[CDES-10\]), quality of life (assessed by 5-item EuroQoL \[EQ-5D\]) and depression/anxiety (assessed by 9-item Patient Health Questionnaire \[PHQ-9\]) and 21-item Depression Anxiety Stress Scale \[DASS-21\]). A per-protocol analysis will be performed to assess the correlations between adherence to these activities and improvement in metabolic control.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Aim: To examine the effects of 1-year team-based multi-component intervention care (MIC) program in obese T2D with poor glycemic control

Hypothesis: The change from a traditional clinic consultation to an individualized, multicomponent care program will improve cardiometabolic parameters in suboptimally treated obese type 2 diabetic participants.

Study design: This is a pilot translational study aiming to compare the effects of a multi-component care program with personalized drug regimen augmented by behavioural therapy with psychological support and peer influence, led by a diabetes specialist team on metabolic and psychobehavioural health in obese type 2 diabetic participants versus usual care (UC).

Settings: The participants would be identified from the Prince of Wales Hospital (PWH). The recruitment period would be 2 years. Since 1995, the PWH runs a comprehensive complication screening program in the ambulatory Diabetes Centre. On a weekly basis, 50-100 patients undergo assessments for risk factors and complications by nurses and healthcare assistants using standard protocols. On average, 8-12 patients attend each session. Since 2007, these data are entered into a web-based Joint Asia Diabetes Evaluation (JADE) Program which incorporates a validated risk engine to generate an integrated report with risk categories, care protocols, trends of risk factor control and decision support to empower both doctors and patients to make informed decisions. After the assessments, During the first two months of intervention, each group would have three 3.5-hour face-to-face workshops with the nurses (week 0, 4 and 8). This would be reduced to 2-hour per workshop 4-monthly thereafter in the following ten months (week 24, 40, 56) i.e. a total of six sessions per group in 1-year intervention. At each workshop, the nurses would use role plays, quizzes, reflective stories and on-site fitness classes to instill these key principles. Each workshop would use similar strategies including goal-setting, health behaviors tracking and peer sharing on personal progress. During this 1-year MIC program, 4 out of 6 workshops would be conducted when participants would be waiting to see endocrinologists (at week 24, 40 and 56). The consultations would be around 15-minute for each participant per visit. In the first two months of intervention, each MIC group also would receive three 20-minute telephone reminders from HCA at 4-weekly intervals (week 0, 4, 8). The call frequency would be reduced to 4-monthly intervals in the following ten months (week 24, 40, 56) i.e. a total of six calls per group. Group members would also be acted as peer supporters for one another in groups of 3 to 4 patients with at least one telephone reminder between workshops. The calls would be guided by structured log sheets focusing on adherence to lifestyle modification, medications and action plan, as well as to identify patients who would require ad-hoc support from the nurses.

The MIC group would return to UC after exit from the 1-year intervention. During the ensuing two years, the MIC group would receive mailing of three simplified JADE follow-up reports at month 18, month 24 and month 30 where the HCA entered BP, HbA1c, body weight and LDL-cholesterol retrieved from the clinic notes or laboratory measurements to provide feedback to the patients. They would be invited to an annual 4-hour group gathering where doctors and nurses would invite patients who achieve and/or maintain risk factor control to share their success stories and provide motivational support to the group.

The UC group would have traditional clinic-based consultation at 3 to 4-monthly intervals in either general medical or diabetes clinic. They would have consultation by different doctors who might or might not refer them to dietitians or nurses for education. There would be no workshops or peer supporters in the UC group.

For this EMERALD project, eligible participants will be randomized to either the MIC or UC group, which will be done independently by a statistician. The group allocation of each participant will be assigned by having a staff independent of the study. Computer generated random codes will be prepared by the statistician prior to participant recruitment and the codes will be stored in a computer. Irrespective of the assignment group, all participants will receive a 2-hour session on how to interpret the JADE report and their risk profiles and will be reinforced on the importance of achieving targets and optimizing self-care.

Statistical Analysis: Descriptive data would be presented as mean ± standard deviation (SD), median (interquartile range) or number (percentage), as appropriate. Triglyceride and urinary albumin-to-creatinine ratio (ACR) would be logarithmically-transformed due to skewed distribution. We would compare baseline characteristics between two groups using either independent t or Wilcoxon rank-sum test for continuous variables, and either χ2 or Fisher's exact test for categorical variables. For continuous and binary outcomes obtained over time, we would perform generalized estimating equations (GEE) analysis in all patients who would have baseline and at least one follow-up measurement. Using UC as referent, we would introduce a group × time (baseline, year 1 and year 3) interaction term in the GEE models to examine the between-group differences from baseline to year 1 and year 3, adjusting for sex and time-varying covariates namely age, disease duration, BMI, use of insulin, oral glucose-, BP- and lipid-lowering agents. When either body weight or waist circumference would be the dependent variable, BMI would be excluded from the model due to collinearity (Pearson correlation 0.84-0.86). The between-group difference for each continuous or binary outcome would be expressed in mean or adjusted odds ratio (aOR) with 95% confidence interval (CI), respectively. GEE analysis can account for correlations between repeated measurements for any individual patient and accommodate missing data caused by dropout, provided these data are missing at random.

Because HbA1c\<7% and KPIs would be null values at baseline in both groups, we would run separate multiple logistic regression analysis that incorporate these data at year 1 and year 3, with group allocation as an independent variable, adjusting for the aforementioned covariates. Data would be analysed using SPSS version 24.0 (Chicago, IL). A two-tailed P-value\<0.05 would be considered significant.

Sample size determination: In this quasi-experimental real-world experiment with comparative group, we estimate that 100 patients in each group would give 80% power at α=0.05 to yield a 0.5% difference at one year, with comparable baseline HbA1c levels and a standard deviation (SD) of 1.2% and 10% attrition rate.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Health Care Delivery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Open label

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EMERALD

Patients will have 1-year multicomponent program (EMERALD) intervention including a total of 6 interactive workshops focusing on empowerment skills, healthy eating and exercise. Please refer to the protocol for further details.

Group Type ACTIVE_COMPARATOR

EMERALD intervention

Intervention Type OTHER

EMERALD consists of a 1-year multi-component structured program led by nurses and held 4-weekly for the first 3 months, followed by maintenance program, peers support and telephone calls.

Usual care

Usual management without any workshop or program

Group Type PLACEBO_COMPARATOR

Usual care

Intervention Type OTHER

Usual care without any workshop or program

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EMERALD intervention

EMERALD consists of a 1-year multi-component structured program led by nurses and held 4-weekly for the first 3 months, followed by maintenance program, peers support and telephone calls.

Intervention Type OTHER

Usual care

Usual care without any workshop or program

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Type 2 diabetic patients
2. Obesity as defined as body mass index (BMI) ³27 kg/m2 and/or waist circumference (WC) ³80cm in women and ³90cm in men
3. Poor glycemic control as defined as HbA1c³8%
4. Age between 18-70 years

Exclusion Criteria

1. Type 1 diabetes
2. Active malignant disease (Patients with malignant disease who have been disease-free for at least 5 years are eligible)
3. Life expectancy less than 12 months
4. Any medical illness or condition as judged by the investigators as ineligible to participate the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chinese University of Hong Kong

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Alice Pik Shan KONG

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alice Kong, MD

Role: PRINCIPAL_INVESTIGATOR

Chinese University of Hong Kong

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Chinese University of Hong Kong, Prince of Wales Hospital

Hong Kong, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EMERALD

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Dapagliflozin Therapy In Cardiac Surgery
NCT05621551 COMPLETED PHASE4